(2S)-2-Cyclopentyl-2-[(5S)-2-[(2R,3R)-3-Cyclopropyl-1-Methylaziridine-2-Carbonyl]-2,7-Diazaspiro[4.4]Nonan-7-Yl]-N-[(6S,8S,14S)-21-[5-(4-Cyclopropylpiperazin-1-Yl)-2-[(1S)-1-Methoxyethyl]Pyridin-3-Yl]-18,18-Dimethyl-9,15-Dioxo-22-(2,2,2-Trifluoroethyl)-5,16-Dioxa-2,10,22,28-Tetrazapentacyclo[18.5.2.12,6.110,14.023,27]Nonacosa-1(26),20,23(27),24-Tetraen-8-Yl]Acetamide

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

9 Countries

Phase II

Phase II: 2

Indications tested

Non-small cell lung cancer 2

Sponsors using this IMP

Revolution Medicines Inc. 2

All trials

2 total

Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS… Recruiting

2025-521147-21-00 Phase II 9 countries Revolution Medicines Inc.
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended

2025-521681-10-00 Phase II 9 countries Revolution Medicines Inc.

Showing 1–2 of 2 trials

← All drugs A–Z